News
Tianwen, which means "questions to heaven," is the name given to China's program of robotic Solar System exploration. Tianwen ...
By comparing fluctuations in brightness captured by two telescopes, researchers say their method boosted image resolution 14-fold.
THE practice of children of ministers or permanent secretaries accessing student loans from the Higher Education Students’ ...
In another 10 years, researchers predicted that it will be half," said Li Cheng, founding director of the Centre on Contemporary China and the World at the University of Hong Kong, at the 2025 RCEP ...
Editor's Note: Ahead of National Science and Technology Workers' Day, which falls on May 30 each year, the State Council Information Office held a group interview on Wednesday in Beijing to discuss ...
TANZANIA has earned global recognition in the field of digital innovation, with three national projects emerging as a champion in the prestigious 2025 World Summit on the Information Society (WSIS) ...
Huonslab Co., Ltd. ("Huonslab"), a subsidiary of Huons Global (KOSDAQ:084110) has announced the successful completion of patient enrollment in its pivotal phase 1 clinical trial of Hydizymetm ...
His creation, AI Gemini, is an AI-driven robot that creates traditional Chinese landscape paintings — the “first-ever artificial intelligence ink artist in the world,” according to 3812 Gallery, which ...
China is building a constellation of AI supercomputers in space — and just launched the first pieces
China has launched the first cluster of satellites for a planned AI supercomputer array. The first-of-its-kind array will enable scientists to perform in-orbit data processing.
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatelli ...
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, ...
Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results